Reimbursement, Vaccine Issues Dominate EU Group's Korea Concerns
Pharma-related regulatory issues are dominant in the latest annual White Paper from the EU Chamber of Commerce in Korea, accounting for 22 of the 96 concerns raised across 18 industries that will be shared with ministries. Quality of life issues around drugs for chronic disorders, risk-sharing agreements, reimbursement and vaccine policies are some of the key questions raised.
You may also be interested in...
MSD’s Global Medical Affairs Lead, Asia Pacific, Aileen Dualan, discusses in an interview with Scrip the diverse, multi-faceted HTA and reimbursement landscape for cancer therapies like Keytruda in the APAC region and progress made, among other issues.
Plus deals involving Novo Nordisk/Neomorph, Mabwell/Jiangsu Haibo, Alteogen/Merck & Co., Gilead/Biocytogen, AlphaGen/ARTBIO and XOMA/Kinnate.
South Korea’s healthcare services face both longer-term systemic challenges and short-term disruption from ongoing doctor walkouts over government plans to boost medical trainees. Meanwhile, the local pharma industry is calling for new measures to support the supply of essential drugs.